What's Happening?
Researchers at the University of Alabama at Birmingham (UAB) Marnix E. Heersink School of Medicine, in collaboration with other institutions, have developed a new multi-ancestry polygenic risk score. This score aims to enhance the identification of individuals
at risk for hypertrophic cardiomyopathy (HCM), a common inherited heart muscle disease. Published in Nature Cardiovascular Research, the study demonstrates that by combining the effects of numerous common genetic variants into a single score, risk assessment can be refined across diverse populations. This advancement is particularly significant for patients whose current genetic tests yield uncertain results. HCM affects approximately one in 500 people and is a leading cause of sudden cardiac death in young individuals, as well as a contributor to heart failure, arrhythmias, and stroke. Traditionally, HCM has been viewed as a 'Mendelian' disease caused by rare pathogenic mutations in heart muscle genes, but these mutations are found in only about a third of patients, and their presence does not always lead to disease development, limiting the utility of existing genetic testing.
Why It's Important?
This new multi-ancestry genetic score represents a significant step towards more equitable and personalized cardiovascular care in the U.S. By incorporating genetic data from diverse populations, including Biobank Japan, the Department of Veterans Affairs Million Veteran Program, and European-ancestry cohorts, the score addresses a critical limitation of previous genetic risk assessments, which were often built primarily from European data. This broader data inclusion helps mitigate the risk of widening health disparities, as noted by co-author Garima Arora, M.D. The score's ability to refine risk assessment, even for carriers of variants of unknown significance, provides clearer guidance for patients and clinicians. For instance, carriers of a pathogenic sarcomere mutation with a high polygenic score had a nearly 70-fold increased risk of HCM, while those with a low score showed no significant increase. This improved prediction can lead to earlier identification and protective measures for at-risk individuals, especially as genetic sequencing costs decrease and disease-specific therapies become more available.
What's Next?
The researchers advocate for the continued expansion of genetic research in diverse populations to further close existing gaps in risk prediction tools. The integration of this polygenic risk score into clinical assessment could become a standard practice, helping clinicians identify and protect patients earlier. As genetic sequencing becomes more accessible and affordable, the practical application of such scores in routine medical care is increasingly feasible. Future efforts will likely focus on validating these findings in even larger and more varied cohorts, and on developing clinical guidelines for incorporating polygenic risk scores into diagnostic pathways for HCM. This could lead to a more comprehensive understanding of individual risk profiles, enabling more targeted interventions and personalized treatment strategies for patients with inherited heart conditions.
Beyond the Headlines
The development of this multi-ancestry genetic score highlights a broader shift in genetic research towards inclusivity and equity. Historically, genetic studies have been disproportionately focused on populations of European descent, leading to tools that may not be as effective or accurate for other groups. This study demonstrates that incorporating diverse genetic data not only improves prediction in underrepresented populations but also enhances accuracy even in European-ancestry individuals by distinguishing true causal signals from statistical noise. This approach has profound ethical implications, ensuring that advancements in genetic medicine benefit all segments of society and do not exacerbate existing health disparities. It also underscores the complex interplay between single gene mutations and broader genetic backgrounds in disease manifestation, moving beyond a purely Mendelian view of inherited conditions to a more nuanced, polygenic understanding.
